Overview

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Anti-Inflammation Effects of Pioglitazone, twice daily (BID), and Pioglitazone/Metformin Combination Therapy BID in Type 2 Diabetes Subjects Treated with Insulin.
Phase:
Phase 4
Details
Lead Sponsor:
Takeda
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc
Metformin
Pioglitazone